4,503
edits
Changes
→Blood Tests
Changes on serum biochemistry analysis may include [[azotemia]], this is common in dogs receiving diuretic therapy and is usually pre-renal in nature. Electrolyte abnormalities, such as mild hyponatraemia and hypokalaemia, are also common in dogs with congestive heart failure.
Changes on serum biochemistry analysis may include [[azotemia]], this is common in dogs receiving diuretic therapy and is usually pre-renal in nature. Electrolyte abnormalities, such as mild hyponatraemia and hypokalaemia, are also common in dogs with congestive heart failure.
'''Cardiac biomarkers''', NT-proBNP and cardiac troponin I (cTnI), may be helpful in detecting DCM. Troponin I may be elevated in cardiac disease and will also be elevated as a consequence of haemodynamically significant arrhythmias. Plasma concentrations of NT-proBNP may be elevated in pre-clinical disease and increase with severity. It is important to note that neither biomarker is specific to DCM and merely indicates the heart is under stress/stretch (NT-proBNP) or that there is damage to cardiomyocytes (cTnI).
Taurine deficiency may contribute to a DCM phenotype in the American Cocker Spaniel, Dalmatian, Labrador Retriever and Golden Retriever. Most dogs with taurine-deficient DCM will have plasma taurine levels <25nmol/L. This is important to recognize, as in these cases cardiac function and prognosis can be substantially improved by taurine supplementation.
'''Taurine''' deficiency may contribute to a DCM phenotype in the American Cocker Spaniel, Dalmatian, Labrador Retriever and Golden Retriever. Most dogs with taurine-deficient DCM will have plasma taurine levels <25nmol/L. This is important to recognize, as in these cases cardiac function and prognosis can be substantially improved by taurine supplementation.
<br>
<br>